BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14716750)

  • 1. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
    Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
    Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model.
    Symon Z; Levi M; Ensminger WD; Smith DE; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):473-8. PubMed ID: 11380236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
    Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
    Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood thiols following amifostine and mesna infusions, a pediatric oncology group study.
    Souid AK; Fahey RC; Aktas MK; Sayin OA; Karjoo S; Newton GL; Sadowitz PD; Dubowy RL; Bernstein ML
    Drug Metab Dispos; 2001 Nov; 29(11):1460-6. PubMed ID: 11602522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical studies on the radioprotective efficacy and pharmacokinetics of subcutaneously administered amifostine.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):2-8. PubMed ID: 12577236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional pharmacokinetics of amifostine in anesthetized dogs: role of the liver, gastrointestinal tract, lungs, and kidneys.
    Levi M; Knol JA; Ensminger WD; DeRemer SJ; Dou C; Lunte SM; Bonner HS; Shaw LM; Smith DE
    Drug Metab Dispos; 2002 Dec; 30(12):1425-30. PubMed ID: 12433814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.
    Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):794-802. PubMed ID: 14529786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse.
    Shaw LM; Bonner HS; Brown DQ
    Drug Metab Dispos; 1994; 22(6):895-902. PubMed ID: 7895607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of spontaneous metastases formation by amifostine.
    Grdina DJ; Kataoka Y; Murley JS; Hunter N; Weichselbaum RR; Milas L
    Int J Cancer; 2002 Jan; 97(2):135-41. PubMed ID: 11774255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypotensive mechanisms of amifostine.
    Ryan SV; Carrithers SL; Parkinson SJ; Skurk C; Nuss C; Pooler PM; Owen CS; Lefer AM; Waldman SA
    J Clin Pharmacol; 1996 Apr; 36(4):365-73. PubMed ID: 8728352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of amifostine and its metabolites in patients.
    Korst AE; Eeltink CM; Vermorken JB; van der Vijgh WJ
    Eur J Cancer; 1997 Aug; 33(9):1425-9. PubMed ID: 9337685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine: the preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies.
    Capizzi R
    Semin Oncol; 1996 Aug; 23(4 Suppl 8):2-17. PubMed ID: 8783661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure.
    Cassatt DR; Fazenbaker CA; Bachy CM; Kifle G; McCarthy MP
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):901-7. PubMed ID: 15708273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study of the pharmacology of local application of amifostine (WR-2721) to the buccal mucosa in guinea pigs.
    Li C; Wang S; Huang T; Chen N; Ou M
    Pharmacology; 2013; 91(5-6):281-6. PubMed ID: 23736649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721.
    Utley JF; Seaver N; Newton GL; Fahey RC
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1525-8. PubMed ID: 6090355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Formulation Strategy to Improve the Feasibility of Amifostine Administration.
    Ranganathan K; Simon E; Lynn J; Snider A; Zhang Y; Nelson N; Donneys A; Rodriguez J; Buchman L; Reyna D; Lipka E; Buchman SR
    Pharm Res; 2018 Mar; 35(5):99. PubMed ID: 29556791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721.
    Calabro-Jones PM; Fahey RC; Smoluk GD; Ward JF
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jan; 47(1):23-7. PubMed ID: 2982751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation.
    Molkentine JM; Fujimoto TN; Horvath TD; Grossberg AJ; Garcia CJG; Deorukhkar A; de la Cruz Bonilla M; Lin D; Samuel ELG; Chan WK; Lorenzi PL; Piwnica-Worms H; Dantzer R; Tour JM; Mason KA; Taniguchi CM
    Sci Rep; 2019 Feb; 9(1):1949. PubMed ID: 30760738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
    Dorr RT; Lagel K; McLean S
    Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.